Gender Related Issues in the Management of Heart Failure

Author(s): Stefan Anker, Giuseppe Caminiti, Maurizio Volterrani

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 11 , 2011

Become EABM
Become Reviewer


Heart failure (HF) represents a growing health issue with significant morbidity, expense, and mortality in western world. Despite a similar prevalence between gender our knowledge about this disease mostly come from studies perfomed in men. Instead, until now women have been under-represented in HF trials and this limits our knowledge of HF in women to extrapolation of findings from men. However according to the available data women with HF differ from men regarding pathophysiology, clinical presentation and prognosis. Women with HF often present at an older age, have a better systolic function, suffer from more comorbidities, have an higher rate of hospital admissions and have a better age-adjusted survival compared to men. Moreover pharmacodynamic specificities related to gender have been described. Taken together these gender-related differences can affect response to several kinds of treatments and the general clinical approach to the patient by the physician. The understanding of these differences may improve the clinicalmanagement of HF and possible new gender-specific diagnostic and therapeutic options may be developed. To this aim, it remains mandatory. to increase the number of female patients with HF enrolled in clinical trials.

Keywords: Heart failure, gender, management, epidemiology, Amiodarone, ventricular, pharmacokinetics, aetiology, diastolic, myocyte, angiotensin, antimitogenic, natriuretic, Prognosis, Bisoprolol, norepinephrine, bradykinin, spironolactone

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1070 - 1078]
Pages: 9
DOI: 10.2174/138161211795656864
Price: $65

Article Metrics

PDF: 10